The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to improve patient outcomes. Discussions include the current landscape for advanced health care management – reviewing emerging treatment paradigms, approaches and considerations – all by authoritative industry voices.
Biosimilars review & Report (BR&R) provides education, commentary and updates on the biosimilar marketplace. Visit https://biosimilarsrr.com/ for a frequently updated resource on the entire field, including biosimilar product profiles, approvals and policy and coverage decisions. We publish regular blogs you can subscribe to receive notifications of new posts by email.
The Festival of Biologics is the meeting place for the life science community to bridge the gap between academia and industry in Antibody Therapies, Immunotherapies and Biosimilars, covering Discovery, Development, Clinical Trials, Manufacturing, Commercialisation, and more. The Festival encourages conversation across the entire biologics industry so you can inspire change, champion innovation, and address complex challenges that the biologics industry is facing.
Generics and Biosimilars Initiative (GaBI) was founded in 2008. GaBI aims to foster the worldwide efficient use of high quality and safe medicines at an affordable price, thus advancing and supporting the idea of accessible, affordable and sustainable health care.
The objective of GaBI is to raise the scientific status of generic and biosimilar medicines, via well-documented and up-to-date information about generic and biosimilar medicines both in print (www.gabi-journal.net) and electronically (www.gabionline.net) in an open access format, providing high quality, scientifically sound and reliable information to healthcare professionals including physicians, pharmacists and nurses, consumers, drug developers, third-party payers, legislators and assessors; who are in need of a reliable, critical and independent source of information on all aspects of generic and biosimilar medicines.
Subscribe to gain easy access of information on the latest scientific research and developments in generic and biosimilar medicines via GaBI Online to editorial@gabionline.net; or submit a manuscript to GaBI Journal to editorial@gabi-journal.net.
GaBI’s mission – Building trust in cost-effective treatments
The Global Generics and Biosimilar Awards celebrate the greatest achievements and innovations across the development, authorisation, marketing and distribution of global, off-patent pharmaceuticals. These illustrious awards provide a unique opportunity for the industry to come together to discuss future opportunities and challenges and shine a light on the companies and individuals driving positive change. Winners will be recognised across a range of categories, including Biosimilar Initiative of the Year, Leader of the Year, API Supplier of the Year and more.
Find out more about the awards here: https://www.citeline.com/awards/ggbawards
JackLeckerman Company is dedicated to increasing access to medicines in Latin America by fostering collaboration between government officials and the pharmaceutical industry. As a leading business event organizer, JL specializes in global summits, strategic conferences, open forums, and professional training programs for the pharmaceutical and biotechnology sectors across Europe, North America, and Latin America.
Our events focus on promoting the development and accessibility of biosimilars, addressing critical industry topics, facilitating knowledge exchange, and encouraging strategic discussions. In 2024, JackLeckerman will host several Biosimilars LatAm forums to support this mission:
English
Arabic
Chinese (Simplified)
Dutch
French
German
Italian
Portuguese
Russian
Spanish
